Cancer Medical Coding: ICD-10 Neoplasm Rules, History-Of & Chemo Codes

Cancer medical coding carries more financial and compliance risk than almost any other specialty. A single oncology encounter can involve a primary malignancy, metastatic sites, chemotherapy administration, high-cost drugs, and side effects such as anemia or pain. Each element has its own ICD-10-CM and CPT® rules, and small sequencing errors can lead to denials, underpayments, or risk adjustment gaps.

This guide explains the core rules for cancer medical coding in 2026–27, including neoplasm table lookups, active versus history-of cancer, metastatic coding, encounter sequencing, and chemotherapy administration. It also covers the FY 2027 ICD-10-CM changes that took effect October 1, 2026.

Why Cancer Medical Coding Is High-Risk

Oncology claims are high-value and closely reviewed. Payers often require prior authorization for chemotherapy, immunotherapy, and radiation. Drug claims can run into tens of thousands of dollars per encounter. In addition, cancer diagnoses map to HCC categories, so a missed or incorrect code can understate a patient’s risk score under Medicare Advantage.

As a result, accurate oncology coding protects three things at once: reimbursement, compliance, and risk-adjusted revenue.

How to Code a Neoplasm in ICD-10-CM

Coders should never start in the Neoplasm Table. Instead, start with the Alphabetic Index and look up the histology or morphology documented in the pathology report, such as adenocarcinoma or melanoma. The index then directs you to the correct column of the Neoplasm Table or to a specific code.

The Neoplasm Table organizes codes by site and behavior:

• Malignant primary — the site where the cancer originated

• Malignant secondary — sites where the cancer has spread

• Ca in situ — malignant cells that have not invaded surrounding tissue

• Benign — non-malignant growths

• Uncertain behavior — histology that cannot yet be classified as benign or malignant

• Unspecified behavior — used when the behavior is not documented

For the complete chapter rules, review the National Cancer Institute’s summary of ICD-10-CM neoplasm guidelines and the official files on the CMS ICD-10 page.

Active Cancer vs. History of Cancer

This is one of the most common cancer coding errors. The deciding factor is whether treatment is still directed at the malignancy.

Physicians often document “history of breast cancer” when the patient is still on tamoxifen. In that case, the cancer is still under treatment, so the active code applies. A provider query is the safest way to resolve unclear documentation.

Coding Metastatic Cancer

When cancer spreads, code both the primary site and each secondary site. Secondary malignancies are reported with codes from categories C77–C79. If the primary site is unknown, use C80.1, malignant (primary) neoplasm, unspecified.

The FY 2027 update made metastatic coding more specific. New codes C78.31 (secondary malignant neoplasm of larynx), C78.32 (pharynx), and C79.83 (oral cavity) now replace the less specific “other site” codes for these locations. In addition, the instruction between breast cancer (C50.-) and carcinoma in situ of breast (D05.-) changed from Excludes2 to Excludes1, so the two can no longer be reported together.

One exception to remember: lymphoma that involves lymph nodes is coded as lymphoma (C81–C88), not as a secondary neoplasm of the lymph nodes.

Sequencing Chemotherapy, Immunotherapy, and Radiation Encounters

Sequencing depends on the reason for the encounter:

• Encounter solely for treatment — List Z51.11 (antineoplastic chemotherapy), Z51.12 (immunotherapy), or Z51.0 (radiation therapy) first, followed by the malignancy.

• Chemotherapy and radiation in the same encounter — Either Z code may be sequenced first.

• Anemia associated with the malignancy — When only the anemia is treated, sequence the malignancy first, followed by D63.0.

• Anemia caused by chemotherapy — Sequence the anemia code (such as D64.81) first, followed by the neoplasm and the adverse effect code T45.1X5-.

• Encounter for pain control — G89.3 (neoplasm-related pain) may be listed first when pain management is the reason for the visit.

Chemotherapy Administration CPT Codes

Chemotherapy administration codes depend on route and time. Infusion start and stop times must be documented, or the service may be downcoded to a push.

In facility settings, chemotherapy services rank above therapeutic infusions, which rank above hydration when choosing the initial service. Hydration (96360) also requires at least 31 minutes to be reported.

Drug Billing: J-Codes, Units, and Waste Modifiers

Oncology drugs are billed with HCPCS J-codes, and units must match the HCPCS descriptor, not the vial size. For Medicare Part B single-dose containers, report the JW modifier for any discarded amount and the JZ modifier when no drug was discarded. Missing or incorrect waste modifiers are a frequent reason for oncology drug denials.

Because drug claims carry the largest dollar amounts, they should be reconciled against the administration record before submission. Our oncology charge capture checklist covers the revenue items practices most often miss.

Cancer Medical Coding Checklist

Before submitting an oncology claim, confirm:

     ✓ Histology — Was the morphology looked up in the Alphabetic Index first?

     ✓ Status — Is the cancer active, in remission, or history-of?

     ✓ Metastasis — Are all secondary sites coded with FY 2027 specificity?

     ✓ Sequencing — Does the first-listed code match the reason for the encounter?

     ✓ Administration — Are start and stop times documented for every infusion?

     ✓ Drugs — Do units, J-codes, and JW/JZ modifiers match the administration record?

     ✓ Authorization — Does the approved regimen match what was given?

For HCC-specific guidance, see our guide to hepatocellular carcinoma coding and our article on E/M coding in oncology.

Conclusion

Cancer medical coding requires precision at every step, from histology lookup to drug units. The most costly errors are usually not exotic. They are history-of codes used for active cancer, missed metastatic sites, incorrect sequencing, and undocumented infusion times. The FY 2027 changes add more metastatic specificity, so coding workflows and templates should be updated now.

MBW RCM provides oncology billing services and radiation oncology billing services with certified coders who review documentation, sequencing, and drug claims before submission. We help cancer centers and oncology practices reduce denials and protect high-value reimbursement.

Download the Oncology Coding Best Practices Guide

Want a quick reference for your coding team? Fill out the form below to download MBW RCM’s Oncology Coding Best Practices Guide, or request a review of your oncology claims to find where reimbursement may be at risk.